Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   36119   clinical trials with a EudraCT protocol, of which   5940   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-000335-11
    Sponsor's Protocol Code Number:MK8669-064
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-08-02
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2012-000335-11
    A.3Full title of the trial
    A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients.
    Studio randomizzato di fase II sulla combinazione di Ridaforolimus ed Exemestane in confronto a Ridaforolimus, Dalotuzumab ed Exemestane in pazienti con cancro alla mammella ad alta proliferazione e positività al recettore degli estrogeni.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A phase IIb study of ridaforolimus, dalotzumab and exemestane in combination in advanced breast cancer.
    Studio di fase II b sulla combinazione di Ridaforolimus, Dalotuzumab ed Exemestane nel cancro alla mammella in fase avanzata.
    A.3.2Name or abbreviated title of the trial where available
    A phase IIb study of ridaforolimus, dalotzumab and exemestane in combination in advanced breast canc
    Studio di fase II b sulla combinazione di R/D/E
    A.4.1Sponsor's protocol code numberMK8669-064
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMERCK SHARP & DOHME CORP.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMERCK SHARP & DOHME CORP.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMSD Italia S.r.l.
    B.5.2Functional name of contact pointDivisione Ricerca Clinica
    B.5.3 Address:
    B.5.3.1Street AddressVia Fratelli Cervi, snc - Centro Direzionale Milano Due - Palazzo Borromini
    B.5.3.2Town/ citySegrate (MI)
    B.5.3.3Post code20090
    B.5.3.4CountryItaly
    B.5.4Telephone number+39 02 21018402
    B.5.5Fax number+39 02 21018629
    B.5.6E-mailgcto.italy@merck.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRidaforolimus
    D.3.2Product code MK-8669
    D.3.4Pharmaceutical form Gastro-resistant tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRidaforolimus
    D.3.9.1CAS number 572924-54-0
    D.3.9.2Current sponsor codeMK-8669
    D.3.9.3Other descriptive nameRidaforolimus
    D.3.9.4EV Substance CodeSUB32091
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDalotuzumab
    D.3.2Product code MK-0646
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDalotuzumab
    D.3.9.1CAS number 1005389-60-5
    D.3.9.2Current sponsor codeMK-0646
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Exemestane 25mg Film-coated Tablets
    D.2.1.1.2Name of the Marketing Authorisation holderActavis Group PTC ehf
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEXEMESTANE
    D.3.9.1CAS number 107868-30-4
    D.3.9.4EV Substance CodeSUB07492MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    ER positive, high proliferation breast.
    Cancro alla mammella positivo al recettore degli estrogeni, localmente avanzato o metastatico, ad alta proliferazione.
    E.1.1.1Medical condition in easily understood language
    Breast cancer.
    Cancro alla mammella.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level SOC
    E.1.2Classification code 10029104
    E.1.2Term Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to evaluate the progression free survival (PFS) for the triplet combination of ridaforolimus, dalotuzumab and exemestane (R/D/E) compared to the combination of ridaforolimus and exemestane (R/E) in post-menopausal patients with high proliferation, estrogen receptor positive breast cancer that have progressed following treatment with a non-steroidal aromatase inhibitor.
    L'obiettivo primario dello studio è valutare la sopravvivenza libera da progressione (PFS) per la triplice combinazione di ridaforolimus, dalotuzumab ed exemestane (R/D/E) rispetto alla combinazione di ridaforolimus ed exemestane (R/E) in pazienti in post-menopausa affette da cancro alla mammella ad alta proliferazione positivo al recettore degli estrogeni in cui si è verificata una progressione dopo il trattamento con un inibitore dell'aromatasi non steroideo. Ipotesi: La combinazione di R/D/E aumenterà la sopravvivenza libera da progressione rispetto a R/E.
    E.2.2Secondary objectives of the trial
    In post-menopausal patients with high proliferation, estrogen receptor positive breast cancer who have progressed following treatment with a non-steroidal aromatase inhibitor, the secondary objectives of this trial are the following: • To evaluate the effectiveness of the triplet combination of ridaforolimus, exemestane and dalotuzumab (R/D/E) compared to ridaforolimus and exemestane (R/E) with respect to percent (%) reduction from baseline in the sum of imaging measurements (target lesion line lengths or volumetric images) at 16 weeks. • To evaluate the objective response rate, as measured by RECIST 1.1 of the triplet combination of R/D/E compared to the combination of R/E. • To estimate the overall survival for the triplet combination of R/D/E compared to the combination of R/E.
    Nelle pazienti in post-menopausa affette da cancro alla mammella ad alta proliferazione positivo al recettore degli estrogeni, che hanno mostrato una progressione dopo il trattamento con inibitore dell'aromatasi non steroideo, gli obiettivi secondari di questa sperimentazione sono i seguenti: . Valutare l'efficacia della triplice combinazione di ridaforolimus, exemestane e dalotuzumab (R/D/E) rispetto a ridaforolimus ed exemestane (R/E) in base alla percentuale (%) di riduzione dal basale nella somma delle misure di imaging (diametri o volumi della lesione target )dopo 16 settimane. Valutare il tasso di risposta oggettiva, come misurato dal RECIST1 11 e della triplice combinazione di R/D/E rispetto alla combinazione R/E.Valutare la sopravvivenza totale per la triplice combinazione di R/D/E rispetto alla combinazione di R/E.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Metastatic, ER positive, HER2 negative Breast Cancer 2. High Proliferative (as measured by a Ki67 labeling index >15%) 3. Post menopausal 4. Previous treatment with either letrozole or anastrozole 5. AT least 1 measurable lesion 6. At least 18 years of age 7. Greater than or equal to 1 on the ECOG performance status. 8. Life expectance greater than 3 months
    1. Cancro alla mammella metastatico positivo al recettore degli estrogeni e negativo ad HER2. 2. Ad alta proliferazione (come determinato dall'indice di marcatura Ki67 &gt;15%.3. In post-menopausa. 4. Precedenti trattamenti con Letrozolo o Anastrozolo. 5. Almeno una lesione misurabile. 6. Almeno 18 anni di età. 7. Valutazione dello stato ECOG &gt; 1. 8. Aspettativa di vita &gt; di 3 mesi.
    E.4Principal exclusion criteria
    1. Patient is on other therapy for their cancer (Bisphosphonates and denosumab for the treatment of bone metastases are allowed, if they were initiated at least 28 days prior to randomization.) 2. Patient is in another study or is receiving an experimental agent. 3. Patient has previously received rapamycin or rapamycin analogs, including ridaforolimus, temsirolimus, or everolimus. 4. Patient has received prior treatment with IGF-1R inhibitors, PI3K inhibitors, or other experimental agents that target PI3K, AKT, or mTOR pathway 5. Patient who has had chemotherapy, radiotherapy, or biological therapy within 4 weeks [(6 weeks for nitrosoureas, mitomycin C, or bevacizumab and 2 weeks for hormonal therapy and kinase inhibitors)] prior to entering the study or who has not recovered from adverse events from prior treatment to at least grade 1 or baseline. 6. Patient has active brain metastasis or leptomeningeal carcinomatosis; 7. Patient has poorly controlled Type 1 or 2 diabetes, defined as a hemoglobin A1C greater than 8% or a fasting glucose of > 160 mg/dL. 8. Patient is known to be HIV positive. 9. Patient has a known history of active Hepatitis B or C. Patients who are seropositive for Hepatitis B surface antibody as their only evidence of prior hepatitis exposure are allowed. 10. Patient has a requirement for concurrent treatment with medications that are inducers or inhibitors of cytochrome P450 (CYP3A). Patients should be off these medications for at least 2 weeks prior to the first dose of ridaforolimus. Concomitant medications that are metabolized by CYP3A are allowed (e.g., simvastatin or atorvastatin). See Appendix 6.1 for examples of CYP3A inducers and inhibitors.
    1. La paziente sta ricevendo un'altra terapia tumorale sistemica concomitante, inclusi agenti tumorali e inibitori HER-2. . Bifosfonati e denosumab per il trattamento delle metastasi ossee sono permessi, se sono stati iniziati prima della randomizzazione. 2. La paziente sta attualmente partecipando o ha partecipato ad uno studio con un composto o dispositivo sperimentale. 3. La paziente ha ricevuto in precedenza rapamicina o analoghi della rapamicina, incluso ridaforolimus, temsirolimus o everolimus. 4. La paziente ha ricevuto un trattamento precedente con inibitori IGF-1R, PI3K o altri agenti sperimentali che hanno come target la via metabolica PI3K, AKT o mTOR. 5. Una paziente che si sia sottoposta a chemioterapia, radioterapia o terapia biologica entro 4 settimane (6 settimane per nitrosouree, mitomicina C o bevacizumab e 2 settimane per una terapia ormonale e inibitori della chinasi) prima di entrare nello studio oppure che non abbia superato eventi avversi da un precedente trattamento ad almeno grado 1 o al basale. 6. La paziente ha un diabete di tipo 1 o 2 non pienamente controllato, definito come emoglobina A1C superiore all'8% o glucosio a digiuno &gt; 160 mg/dl. 7. La paziente è positiva all'HIV. 8. La paziente ha un'anamnesi nota di epatite B o C attiva. Saranno idonee le pazienti che sono sieropositive per gli anticorpi contro l'antigene di superficie dell'epatite B come unica evidenza di precedente esposizione all'epatite. 8. La paziente ha necessità di un trattamento concomitante con medicinali che sono induttori o inibitori del citocromo P450 (CYP3A). Le pazienti devono aver interrotto questi medicinali da almeno 2 settimane prima della prima dose di ridaforolimus. Sono consentiti medicinali concomitanti che sono metabolizzati dal CYP3A (ad esempio simvastatina o atorvastatina). Vedere appendice 6.1 per esempi di induttori ed inibitori).
    E.5 End points
    E.5.1Primary end point(s)
    1. Progression Free Survival according to RECIST 1.1.
    Sopravvivenza libera da progressione in accordo al RECIST 1.1.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Every 8 calendar weeks while on treatment.
    Ogni 8 settimane di calendario durante il trattamento.
    E.5.2Secondary end point(s)
    1. Percent (%) change from baseline in the sum of target lesions by linear CT analysis at 16 weeks. 2. Percent (%) change from baseline in the sum of target lesions by tumor volume analysis at 16 weeks 3. Objective response rate, as measured by RECIST 1.1. 4. Overall survival will be assessed every 3 months.
    1. Variazione in percentuale rispetto al basale nella somma delle lesioni bersaglio mediante analisi lineare CT a 16 settimane. 2. Variazione in percentuale rispetto al basale nella somma delle lesioni mediante analisi del volume tumorale a 16 settimane. 3. Tasso di risposta obiettiva misurato secondo RECIST 1.1. 4. La sopravvivenza globale sarà valutata ogni 3 mesi.
    E.5.2.1Timepoint(s) of evaluation of this end point
    16 weeks for endpoints 1 and 2. Every 8 weeks for objective 3 every three months after disease progression.
    16 settimane per il primo ed il secondo endpoint. Ogni 8 settimane per il terzo ogni 3 mesi dopo la progressione della malattia.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Ridaforolimus-Exemestane
    Ridaforolimus-Exemestane
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA31
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Brazil
    Canada
    Colombia
    Israel
    Korea, Republic of
    Peru
    Taiwan
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS or; SPONSOR has right to terminate the study at any time. Reasons may include: quality or quantity of data recording is inaccurate or incomplete; poor adherence to protocol and regulatory requirements; the incidence or severity of adverse drug reaction in this or other studies indicates a potential health hazard to patients; plans to modify or discontinue the development of the study drug; or if study drug(s) is approved for marketing and available commercially. See protocol.
    Lo Sponsor ha diritto a sospendere lo studio in qualsiasi momento.Le ragioni possono includere:registrazione dei dati mprecisa o incompleta;scarsa aderenza al protocollo ed ai requisiti normativi;incidenza o gravità delle reazioni avverse al farmaco
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months32
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months32
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 75
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 75
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 62
    F.4.2.2In the whole clinical trial 150
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    n.a.
    n.a.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-09-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-06-12
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-03-15
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA